Sheila Gujrathi (Gossamer Bio)
Gossamer shares take another beating as its lead drug fails 2 key clinical studies, highlighting harsh reviews for DP2
Ever since a key DP2 drug at Novartis called fevipiprant failed a pivotal lineup of clinical studies by the end of last year, a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
